FOLH1 and prostate cancer: While these were a significant upgrade to the previous imaging standard for prostate cancer, research continued on prostate-targeted PET agents, and in December of 2020, the FDA approved Gallium-68 PSMA-11 (Ga-68 PSMA-11, Illuccix, Locametz).